FDA OKs Teva’s generic pemetrexed for lung cancer

The FDA approves Teva Pharmaceutical Industries (TEVA -2.6%) unit Actavis’ generic pemetrexed for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has not progressed after four cycles of first-line platinum-based chemo.

https://seekingalpha.com/news/3608341-fda-oks-tevas-generic-pemetrexed-for-lung-cancer